Activation of the immune system in cancer patients

Gool, Stefaan W. Van; Hove, Ludwig Van den; Ceuppens, Jan L.

doi:10.1002/(sici)1096-911x(200001)34:1<1::aid-mpo1>3.0.co;2-l

Cited by 10 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both effector cell types are believed to be necessary to induce an effective cell‐mediated immune response (34, 72, 121). Direct recognition of tumor cells by unprimed T cells, in contrast, induces T cell anergy rather than immunity as the costimulatory molecules are missing on the tumor cells (127, 126).…”

Section: Principles Of DC Therapy In Gliomamentioning

confidence: 99%

Dendritic Cell Therapy of High‐Grade Gliomas

Gool¹,

Maes²,

Ardon³

et al. 2009

Brain Pathology

View full text Add to dashboard Cite

The prognosis of patients with malignant glioma is poor in spite of multimodal treatment approaches consisting of neurosurgery, radiochemotherapy and maintenance chemotherapy. Among innovative treatment strategies like targeted therapy, antiangiogenesis and gene therapy approaches, immunotherapy emerges as a meaningful and feasible treatment approach for inducing long-term survival in at least a subpopulation of these patients. Setting up immunotherapy for an inherent immunosuppressive tumor located in an immune-privileged environment requires integration of a lot of scientific input and knowledge of both tumor immunology and neuro-oncology. The field of immunotherapy is moving into the direction of active specific immunotherapy using autologous dendritic cells (DCs) as vehicle for immunization. In the translational research program of the authors, the whole cascade from bench to bed to bench of active specific immunotherapy for malignant glioma is covered, including proof of principle experiments to demonstrate immunogenicity of patient-derived mature DCs loaded with autologous tumor lysate, preclinical in vivo experiments in a murine orthotopic glioma model, early phase I/II clinical trials for relapsing patients, a phase II trial for patients with newly diagnosed glioblastoma (GBM) for whom immunotherapy is integrated in the current multimodal treatment, and laboratory analyses of patient samples. The strategies and results of this program are discussed in the light of the internationally available scientific literature in this fast-moving field of basic science and translational clinical research.

show abstract

Section: Principles Of DC Therapy In Gliomamentioning

confidence: 99%

Dendritic Cell Therapy of High‐Grade Gliomas

Gool¹,

Maes²,

Ardon³

et al. 2009

Brain Pathology

View full text Add to dashboard Cite

show abstract

“…Moreover, the antiviral potential of EACA would be also beneficial for application in oncological clinics [32,114]. It is well known that chemotherapy causes the suppression of the immune system, thus increasing the risk of viral infections that predominantly attack the respiratory tract [115,116]. In this regard, the synergetic activity of EACA against adenoviruses (protease-containing viruses) and radiation-induced effects could be harnessed for cancer management.…”

Section: Discussionmentioning

confidence: 99%

A New Insight on the Radioprotective Potential of Epsilon-Aminocaproic Acid

et al. 2020

View full text Add to dashboard Cite

Background and objectives: The aim of the study was to scrutinize the ability of epsilon-aminocaproic acid (EACA) to prevent radiation-induced damage to human cells. Materials and Methods: Human peripheral blood mononuclear cells (PBMCs) were exposed to ionizing radiation at three low doses (22.62 mGy, 45.27 mGy, and 67.88 mGy) in the presence of EACA at the concentration of 50 ng/mL. Results: EACA was able to prevent cell death induced by low-dose X-ray radiation and suppress the formation of reactive oxygen species (ROS). EACA also demonstrated a capacity to protect DNA from radiation-induced damage. The data indicated that EACA is capable of suppression of radiation-induced apoptosis. Comparative tests of antioxidative activity of EACA and a range of free radical scavengers showed an ability of EACA to effectively inhibit the generation of ROS. Conclusions: This study showed that the pretreatment of PBMCs with EACA is able to protect the cells from radiation-elicited damage, including free radicals’ formation, DNA damage, and apoptosis.

show abstract

Light Pollution as a New Risk Factor for Human Breast and Prostate Cancers

Haim

Portnov

2013

View full text Add to dashboard Cite

Activation of the immune system in cancer patients

Cited by 10 publications

References 70 publications

Dendritic Cell Therapy of High‐Grade Gliomas

Dendritic Cell Therapy of High‐Grade Gliomas

A New Insight on the Radioprotective Potential of Epsilon-Aminocaproic Acid

Light Pollution as a New Risk Factor for Human Breast and Prostate Cancers

Contact Info

Product

Resources

About